Continued Low-Dose Decitabine (Dac) Is An Active First-Line Treatment Of Older Aml Patients: First Results Of A Multicenter Phase Ii Study.

Background: Few therapeutic options exist for older AML patients (pts) in whom induction chemotherapy is not feasible. Encouraged by the marked activity and low toxicity of the demethylating agent DAC in high-risk MDS, we initiated a phase II trial in untreated AML patients >60 years not eligible for induction.